新的放射性标记埃克森丁类似物显示减少了脏保留率
Lieke Joosten1, Cathelijne Frielink1, Theodorus J P Jansen1
1Department of Medical Imaging, Nuclear Medicineof Medical Imaging, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Molecular pharmaceutics
|June 2, 2023
概括
新的exendin类似物与甲氨酸-单氨酸链接剂显著降低保留,以改善葡萄糖类-1受体 (GLP-1R) 成像和治疗. 这些类似物提供了更好的瘤-脏比率,可能提高胰岛素瘤检测和治疗应用.
科学领域:
- 核医学就是核医学.
- 放射性药物化学 放射性药物化学
- 在瘤学瘤学.
背景情况:
- 使用放射性标记的exendin进行正子发射断层扫描 (PET) 成像,其目标是用于胰岛素瘤检测的葡萄糖类-1受体 (GLP-1R).
- 放射性标记的exendin在中的高积累阻碍了检测小,附近的胰岛素瘤,并限制了其在放射性核酸治疗中的使用.
研究的目的:
- 开发和评估新型的exendin类似物,旨在减少保留,以改善GLP-1R成像和治疗.
- 评估具有可切割的甲氨酸-单氨酸 (Met-Ile) 连接器的新型exendin类型的亲和力,脏保留和瘤向性.
主要方法:
- 合成了两种新的exendin类似物,NOTA-Met-Ile-exendin-4和DOTA-Met-Ile-exendin-4,并与没有链接器的类似物进行了比较.
- 使用竞争性结合试验评估GLP-1R亲和力.
- 在携带GLP-1R表达胰岛素瘤的小鼠模型中进行了生物分布研究和PET/CT成像,使用[68Ga]Ga-NOTA-MI-exendin-4和[177Lu]Lu-DOTA-MI-exendin-4进行了[68Ga]Ga-NOTA-MI-exendin-4和[177Lu]Lu-DOTA-MI-exendin-4.
主要成果:
- 新的exendin类似物在低纳米分子范围内表现出GLP-1R亲和力.
- [68Ga]Ga-NOTA-MI-exendin-4的脏吸收量显著降低 (34.2 ± 4.2 %IA/g在4h) 与参考 (128 ± 10 %IA/g) 相比,与类似的瘤吸收量 (25.0 ± 8.0 %IA/g) 相比,改善了瘤与脏的比率.
- [177Lu]Lu-DOTA-MI-exendin-4在注射后的24小时和72小时内也显著减少了脏保留,导致瘤与脏的比率提高.
结论:
- 结合Met-Ile链接器的Exendin类似物显著减少了2-3倍的脏保留,改善了成像和治疗应用的瘤与脏的比率.
- 这些新型类似物有望通过使用PET/CT改善附近小胰岛素瘤的检测,并促进基于exendin的放射性核素治疗.
关键词:
在Ga-68中,它是最重要的.卢-177 卢-177 卢-177 卢-177 卢-177 卢-177 卢聚乙烯/聚乙烯/聚乙烯现在已经退出了.胰岛素马萨斯 (insulinomas) 是一种胰岛素.脏保留 脏保留 脏保留更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Renal Drug Excretion: Tubular Reabsorption
233
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
233
Drug Elimination by Renal Route: Tubular Reabsorption
3.5K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.5K
Renal Drug Clearance: Comparison Between Renal Excretion Methods
187
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
187
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Renal Drug Excretion: Tubular Secretion
232
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
232


